IRON Financial LLC Decreases Holdings in Johnson & Johnson (NYSE:JNJ)

IRON Financial LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,653 shares of the company’s stock after selling 80 shares during the quarter. IRON Financial LLC’s holdings in Johnson & Johnson were worth $916,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Cordatus Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 1.7% in the third quarter. Cordatus Wealth Management LLC now owns 31,913 shares of the company’s stock valued at $5,172,000 after purchasing an additional 523 shares during the period. United Asset Strategies Inc. boosted its position in Johnson & Johnson by 510.6% in the 3rd quarter. United Asset Strategies Inc. now owns 60,192 shares of the company’s stock valued at $9,755,000 after buying an additional 50,334 shares during the last quarter. Rosenberg Matthew Hamilton grew its stake in shares of Johnson & Johnson by 12.7% during the third quarter. Rosenberg Matthew Hamilton now owns 3,319 shares of the company’s stock valued at $538,000 after acquiring an additional 374 shares in the last quarter. Tilson Financial Group Inc. purchased a new stake in shares of Johnson & Johnson during the third quarter worth about $258,000. Finally, Tevis Investment Management lifted its stake in shares of Johnson & Johnson by 5.4% in the third quarter. Tevis Investment Management now owns 17,334 shares of the company’s stock worth $2,809,000 after acquiring an additional 884 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $160.13 on Friday. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The stock has a market capitalization of $385.53 billion, a price-to-earnings ratio of 23.17, a PEG ratio of 2.85 and a beta of 0.52. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The stock’s fifty day simple moving average is $163.31 and its 200 day simple moving average is $155.44.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.66 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Analysts Set New Price Targets

Several research analysts have weighed in on JNJ shares. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. TD Securities decreased their target price on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Finally, Sanford C. Bernstein increased their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $175.93.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.